| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w12643 |
| 来源ID | Working Paper 12643 |
| Cost-Offsets of New Medications for Treatment of Schizophrenia | |
| Richard G. Frank; Thomas G. McGuire; Sharon-Lise Normand | |
| 发表日期 | 2006-10-24 |
| 出版年 | 2006 |
| 语种 | 英语 |
| 摘要 | Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia. We extend research in this area by taking a new approach to identification of spending impacts of new drugs. We specify and estimate models of spending on treatment of schizophrenia using 7 years of Florida Medicaid data. The estimates indicate that use of the new drugs result in net spending increases. This may be due to increased adherence to treatment. |
| 主题 | Health, Education, and Welfare ; Health |
| URL | https://www.nber.org/papers/w12643 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/570305 |
| 推荐引用方式 GB/T 7714 | Richard G. Frank,Thomas G. McGuire,Sharon-Lise Normand. Cost-Offsets of New Medications for Treatment of Schizophrenia. 2006. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w12643.pdf（125KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
